Histone Deacetylase Inhibitors Stimulate Cell Migration in Human Endometrial Adenocarcinoma Cells Through Up-regulation of Glycodelin
Overview
Authors
Affiliations
Histone deacetylase inhibitors (HDACIs) have recently emerged as promising anticancer drugs to induce cell cycle arrest, cytodifferentiation, and apoptosis. It is suggested, however, that HDACIs promote cell migration and invasion depending on the cell type. We have reported previously that treatment with HDACIs, including trichostatin A and suberoylanilide hydroxamic acid (SAHA) or progesterone in combination with estrogen, can induce cytodifferentiation of endometrial adenocarcinoma Ishikawa cells through up-regulation of glycodelin, a progesterone-induced endometrial glycoprotein. Given the reported role of glycodelin in cell motility and the migration-modulating potential of HDACIs, we investigated using wound healing assay and transwell migration assay whether ovarian steroid hormones, trichostatin A, or SAHA affects cell migration in endometrial cancer cell lines, Ishikawa and RL95-2. Treatment with ovarian steroid hormones, trichostatin A, and SAHA enhanced cell migration together with up-regulation of glycodelin. SAHA-augmented cell migration was almost completely blocked by gene silencing of glycodelin. Furthermore, overexpression of gycodelin alone resulted in increased cell motility in Ishikawa cells. Our results collectively indicate that glycodelin positively regulates cell motility acting as a mediator of HDACI-enhanced endometrial cell migration, suggesting the involvement of glycodelin in the dynamic endometrial gland morphogenesis during menstrual cycle. Our results raise a possibility that the use of HDACIs in the therapy for glycodelin-inducible endometrial and presumably other gynecological cancers may enhance invasion in cases in which the HDACIs fail to exert differentiation-inducing and/or antiproliferative effects.
Organoids to model the endometrium: implantation and beyond.
Rawlings T, Makwana K, Tryfonos M, Lucas E Reprod Fertil. 2022; 2(3):R85-R101.
PMID: 35118399 PMC: 8801025. DOI: 10.1530/RAF-21-0023.
Uchida H, Maruyama T, Nishikawa-Uchida S, Miyazaki K, Masuda H, Yoshimura Y Reprod Med Biol. 2018; 12(3):79-84.
PMID: 29699134 PMC: 5904763. DOI: 10.1007/s12522-013-0144-2.
The Roles of Glycodelin in Cancer Development and Progression.
Cui J, Liu Y, Wang X Front Immunol. 2017; 8:1685.
PMID: 29238349 PMC: 5712544. DOI: 10.3389/fimmu.2017.01685.
EZH2 inhibition suppresses endometrial cancer progression via miR-361/Twist axis.
Ihira K, Dong P, Xiong Y, Watari H, Konno Y, Hanley S Oncotarget. 2017; 8(8):13509-13520.
PMID: 28088786 PMC: 5355116. DOI: 10.18632/oncotarget.14586.
Targeting the Epithelial-to-Mesenchymal Transition: The Case for Differentiation-Based Therapy.
Pattabiraman D, Weinberg R Cold Spring Harb Symp Quant Biol. 2017; 81:11-19.
PMID: 28057845 PMC: 5722631. DOI: 10.1101/sqb.2016.81.030957.